Centessa Pharmaceuticals Reveals Promising Phase 1 Data

Grafa

2024-09-10

Centessa Pharmaceuticals (NASDAQ:CNTA) has announced positive interim results from its ongoing Phase 1 trial of the orexin receptor 2 (OX2R) agonist, ORX750.

Centessa shares jumped 14% in premarket trading.

The study demonstrated that acutely sleep-deprived healthy volunteers who received ORX750 experienced statistically significant increases in wakefulness and favorable safety profiles.

Mean sleep latency for the 2.5 mg dose was 32 minutes compared to 17 minutes for the placebo (p-value = 0.01).

“The early data generated has exceeded our expectations, giving us the confidence to accelerate the program into the next stage of clinical development earlier than anticipated,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.

The company plans to initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia later in 2024.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2466360944"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2466360944\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2466360944?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-10 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466360944","market":"us","top_or_hot":-1,"title":"Centessa Pharmaceuticals Reveals Promising Phase 1 Data","media":"Grafa","content":"<html><head></head><body><p class=\"t-img-caption\"><img alt=\"\" src=\"https://community-static.tradeup.com/news/a7b50cbda539c1b6af1546dc80d094b6\" tg-height=\"1080\" tg-width=\"1920\" title=\"\"/></p><p>Centessa Pharmaceuticals (NASDAQ:CNTA) has announced positive interim results from its ongoing Phase 1 trial of the orexin receptor 2 (OX2R) agonist, ORX750.</p><p>Centessa shares jumped 14% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/b9f2d45559333346ba1926ee3f72b6e2\" tg-height=\"840\" tg-width=\"790\"/></p><p>The study demonstrated that acutely sleep-deprived healthy volunteers who received ORX750 experienced statistically significant increases in wakefulness and favorable safety profiles.</p><p>Mean sleep latency for the 2.5 mg dose was 32 minutes compared to 17 minutes for the placebo (p-value = 0.01).</p><p>“The early data generated has exceeded our expectations, giving us the confidence to accelerate the program into the next stage of clinical development earlier than anticipated,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.</p><p>The company plans to initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia later in 2024.</p><p> </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Centessa Pharmaceuticals Reveals Promising Phase 1 Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCentessa Pharmaceuticals Reveals Promising Phase 1 Data\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1019687050\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/b5820fc70e21f7eb65d05d7a2a3e6c15);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Grafa </p>\n<p class=\"h-time\">2024-09-10 20:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p class=\"t-img-caption\"><img alt=\"\" src=\"https://community-static.tradeup.com/news/a7b50cbda539c1b6af1546dc80d094b6\" tg-height=\"1080\" tg-width=\"1920\" title=\"\"/></p><p>Centessa Pharmaceuticals (NASDAQ:CNTA) has announced positive interim results from its ongoing Phase 1 trial of the orexin receptor 2 (OX2R) agonist, ORX750.</p><p>Centessa shares jumped 14% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/b9f2d45559333346ba1926ee3f72b6e2\" tg-height=\"840\" tg-width=\"790\"/></p><p>The study demonstrated that acutely sleep-deprived healthy volunteers who received ORX750 experienced statistically significant increases in wakefulness and favorable safety profiles.</p><p>Mean sleep latency for the 2.5 mg dose was 32 minutes compared to 17 minutes for the placebo (p-value = 0.01).</p><p>“The early data generated has exceeded our expectations, giving us the confidence to accelerate the program into the next stage of clinical development earlier than anticipated,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.</p><p>The company plans to initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia later in 2024.</p><p> </p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CNTA","symbol_name":"Centessa Pharmaceuticals plc","start_time":0,"source_url":"https://grafa.com/news/health-centessa-pharmaceuticals-reveals-promising-phase-1-data-273036?referralcode=A314DFDBE96C354756A893C6E3E02493","article_id":"2466360944","we_media_id":"1019687050","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466360944","pubTimestamp":1725969713,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Grafa","introduction":"Grafa generates AI-driven data, news and analysis about NYSE, Nasdaq and ASX stocks as well as forex, crypto and economic news. News is generated in near real-time due to Grafa's unique data-led approach to media content generation.","home_visible":1,"id":"1019687050","head_image":"https://static.tigerbbs.com/b5820fc70e21f7eb65d05d7a2a3e6c15"},"summary":"Centessa Pharmaceuticals  has announced positive interim results from its ongoing Phase 1 trial of the orexin receptor 2  agonist, ORX750.The study demonstrated that acutely sleep-deprived healthy volunteers who received ORX750 experienced statistically significant increases in wakefulness and favorable safety profiles.Mean sleep latency for the 2.5 mg dose was 32 minutes compared to 17 minutes for the placebo .“The early data generated has exceeded our expectations, giving us the confidence to accelerate the program into the next stage of clinical development earlier than anticipated,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.The company plans to initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia later in 2024.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CNTA":"Centessa Pharmaceuticals plc"},"translate_title":"Centessa Pharmaceuticals公布了有希望的一期数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTA":1.1},"content_text":"Centessa Pharmaceuticals (NASDAQ:CNTA) has announced positive interim results from its ongoing Phase 1 trial of the orexin receptor 2 (OX2R) agonist, ORX750.Centessa shares jumped 14% in premarket trading.The study demonstrated that acutely sleep-deprived healthy volunteers who received ORX750 experienced statistically significant increases in wakefulness and favorable safety profiles.Mean sleep latency for the 2.5 mg dose was 32 minutes compared to 17 minutes for the placebo (p-value = 0.01).“The early data generated has exceeded our expectations, giving us the confidence to accelerate the program into the next stage of clinical development earlier than anticipated,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.The company plans to initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia later in 2024.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0}}}